麻疹-腮腺炎-风疹疫苗从卫生政治和经济的角度。

GMS health technology assessment Pub Date : 2007-11-28
Ingrid Rosian-Schikuta, Barbara Fröschl, Claudia Habl, Heidi Stürzlinger
{"title":"麻疹-腮腺炎-风疹疫苗从卫生政治和经济的角度。","authors":"Ingrid Rosian-Schikuta,&nbsp;Barbara Fröschl,&nbsp;Claudia Habl,&nbsp;Heidi Stürzlinger","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Measels, Mumps and Rubella (MMR) are highly contagious infectious diseases which may lead to severe complications. These diseases are vaccine-preventable. The present Health Technology Assessment report (report on technological consequences, HTA report) was commissioned by the German Institute of Medical Documentation and Information (DIMDI) and addresses various aspects of the MMR vaccination, the key question being how the MMR immunisation coverage rate can be increased in Germany.</p><p><strong>Objectives: </strong>The objectives of this report were to describe the benefits of the MMR vaccination for Germany and to analyse how the desired MMR immunisation coverage of >95% can be achieved.</p><p><strong>Methods: </strong>A systematic literature search was performed in 29 literature data bases. Particularly for epidemiological data and information on vaccination programs, this systematic search was supplemented by an extensive hand search, written and oral enquiries, as well as interviews with experts. A total of 200 texts were used to prepare this report.</p><p><strong>Results: </strong>At 92.5% (as of 2004) based on the whole of Germany, the current immunisation coverage for measles in children is above the weighted EC-15-average of 90.67%. Statements can only be made regarding the probability of illness for measles, as no data is available for mumps and rubella. With 2.8 infections (per 100,000 residents) in 2006, Germany has not achieved the WHO target. Of cases submitted to the laboratory, only 32% were validated by diagnostic laboratory findings and 45% confirmed clinical-epidemiologically. There are only few economic analyses of vaccination programs in Germany. In international publications, mainly measels are validated economically. An analysis of the cost of measles for Germany shows potential cost savings. Unfortunately, no complete economic evaluation (cost-effectiveness, cost-benefit, or cost-utility analyses) for MMR vaccination has been performed for Germany. Analyses conducted in the US and a model calculation for a hypothetical Western-European country show a considerable cost saving potential for society in general as well as for the health care system. INTERVENTIONS TO INCREASE THE IMMUNISATION RATE WERE CATEGORIZED IN THREE MAIN GROUPS ACCORDING TO THEIR GOALS: interventions increasing the demand for vaccinations, those improving access to vaccination services and those aiming at the providers (e.g. physicians) of vaccinations.</p><p><strong>Discussion: </strong>Various studies concluded that reminders to clients, provided in written, electronic or oral form, are a highly recommendable intervention. Provider based interventions were also strongly advised. DESPITE EFFORTS MADE DURING THE PAST YEARS TO ACHIEVE HERD IMMUNITY IN GERMANY, SOME DEFICITS REMAIN: i. e. there are still ample regional differences between and within German federal states.</p><p><strong>Conclusions: </strong>In the authors' opinion, a key point in increasing immunisation coverage is the development of a binding vaccination program for Germany with regionally differentiated immunisation targets. During the development of such a program, special emphasis should be placed on determining responsibilities of the federal government, the Laender and health insurance funds (e. g. in the case of a measles outbreak).</p>","PeriodicalId":89142,"journal":{"name":"GMS health technology assessment","volume":"3 ","pages":"Doc12"},"PeriodicalIF":0.0000,"publicationDate":"2007-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/5f/HTA-03-12.PMC3011330.pdf","citationCount":"0","resultStr":"{\"title\":\"The Measels-Mumps-Rubella Vaccination from a health political and economical point of view.\",\"authors\":\"Ingrid Rosian-Schikuta,&nbsp;Barbara Fröschl,&nbsp;Claudia Habl,&nbsp;Heidi Stürzlinger\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Measels, Mumps and Rubella (MMR) are highly contagious infectious diseases which may lead to severe complications. These diseases are vaccine-preventable. The present Health Technology Assessment report (report on technological consequences, HTA report) was commissioned by the German Institute of Medical Documentation and Information (DIMDI) and addresses various aspects of the MMR vaccination, the key question being how the MMR immunisation coverage rate can be increased in Germany.</p><p><strong>Objectives: </strong>The objectives of this report were to describe the benefits of the MMR vaccination for Germany and to analyse how the desired MMR immunisation coverage of >95% can be achieved.</p><p><strong>Methods: </strong>A systematic literature search was performed in 29 literature data bases. Particularly for epidemiological data and information on vaccination programs, this systematic search was supplemented by an extensive hand search, written and oral enquiries, as well as interviews with experts. A total of 200 texts were used to prepare this report.</p><p><strong>Results: </strong>At 92.5% (as of 2004) based on the whole of Germany, the current immunisation coverage for measles in children is above the weighted EC-15-average of 90.67%. Statements can only be made regarding the probability of illness for measles, as no data is available for mumps and rubella. With 2.8 infections (per 100,000 residents) in 2006, Germany has not achieved the WHO target. Of cases submitted to the laboratory, only 32% were validated by diagnostic laboratory findings and 45% confirmed clinical-epidemiologically. There are only few economic analyses of vaccination programs in Germany. In international publications, mainly measels are validated economically. An analysis of the cost of measles for Germany shows potential cost savings. Unfortunately, no complete economic evaluation (cost-effectiveness, cost-benefit, or cost-utility analyses) for MMR vaccination has been performed for Germany. Analyses conducted in the US and a model calculation for a hypothetical Western-European country show a considerable cost saving potential for society in general as well as for the health care system. INTERVENTIONS TO INCREASE THE IMMUNISATION RATE WERE CATEGORIZED IN THREE MAIN GROUPS ACCORDING TO THEIR GOALS: interventions increasing the demand for vaccinations, those improving access to vaccination services and those aiming at the providers (e.g. physicians) of vaccinations.</p><p><strong>Discussion: </strong>Various studies concluded that reminders to clients, provided in written, electronic or oral form, are a highly recommendable intervention. Provider based interventions were also strongly advised. DESPITE EFFORTS MADE DURING THE PAST YEARS TO ACHIEVE HERD IMMUNITY IN GERMANY, SOME DEFICITS REMAIN: i. e. there are still ample regional differences between and within German federal states.</p><p><strong>Conclusions: </strong>In the authors' opinion, a key point in increasing immunisation coverage is the development of a binding vaccination program for Germany with regionally differentiated immunisation targets. During the development of such a program, special emphasis should be placed on determining responsibilities of the federal government, the Laender and health insurance funds (e. g. in the case of a measles outbreak).</p>\",\"PeriodicalId\":89142,\"journal\":{\"name\":\"GMS health technology assessment\",\"volume\":\"3 \",\"pages\":\"Doc12\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-11-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/5f/HTA-03-12.PMC3011330.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GMS health technology assessment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GMS health technology assessment","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

麻疹、腮腺炎和风疹(MMR)是高度传染性的传染病,可导致严重并发症。这些疾病是可以通过疫苗预防的。本卫生技术评估报告(技术后果报告,HTA报告)是由德国医学文献和信息研究所(DIMDI)委托编写的,涉及MMR疫苗接种的各个方面,关键问题是如何在德国提高MMR疫苗接种覆盖率。目的:本报告的目的是描述德国接种MMR疫苗的好处,并分析如何实现>95%的MMR疫苗接种覆盖率。方法:系统检索29个文献数据库。特别是对于流行病学数据和关于疫苗接种规划的信息,这种系统检索还辅以广泛的手工检索、书面和口头询问以及与专家的访谈。编写本报告共使用了200份文本。结果:以整个德国为基础,目前儿童麻疹免疫接种率为92.5%(截至2004年),高于欧盟15国加权平均水平90.67%。由于没有腮腺炎和风疹的数据,因此只能就麻疹发病的可能性作出说明。德国2006年感染人数为2.8人(每10万居民),没有达到世卫组织的目标。在提交给实验室的病例中,只有32%得到诊断性实验室结果的证实,45%得到临床流行病学证实。在德国,只有很少的疫苗接种项目的经济分析。在国际出版物中,主要是麻疹在经济上得到证实。对德国麻疹成本的分析显示了潜在的成本节约。不幸的是,德国没有对MMR疫苗接种进行完整的经济评估(成本效益、成本效益或成本效用分析)。在美国进行的分析和一个假设的西欧国家的模型计算表明,对整个社会以及医疗保健系统来说,这是一个相当大的成本节约潜力。提高免疫接种率的干预措施按其目标分为三大类:增加疫苗接种需求的干预措施、改善获得疫苗接种服务的干预措施和针对疫苗接种提供者(如医生)的干预措施。讨论:各种研究得出结论,以书面、电子或口头形式向客户提供提醒是一种非常值得推荐的干预措施。还强烈建议以提供者为基础的干预措施。尽管过去几年在德国为实现群体免疫作出了努力,但仍然存在一些缺陷:即德国联邦各州之间和各州内部仍然存在很大的地区差异。结论:在作者看来,提高免疫覆盖率的一个关键点是在德国制定具有区域差异免疫目标的有约束力的疫苗接种计划。在制定这一方案期间,应特别强调确定联邦政府、各州和健康保险基金的责任(例如在麻疹爆发的情况下)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Measels-Mumps-Rubella Vaccination from a health political and economical point of view.

Introduction: Measels, Mumps and Rubella (MMR) are highly contagious infectious diseases which may lead to severe complications. These diseases are vaccine-preventable. The present Health Technology Assessment report (report on technological consequences, HTA report) was commissioned by the German Institute of Medical Documentation and Information (DIMDI) and addresses various aspects of the MMR vaccination, the key question being how the MMR immunisation coverage rate can be increased in Germany.

Objectives: The objectives of this report were to describe the benefits of the MMR vaccination for Germany and to analyse how the desired MMR immunisation coverage of >95% can be achieved.

Methods: A systematic literature search was performed in 29 literature data bases. Particularly for epidemiological data and information on vaccination programs, this systematic search was supplemented by an extensive hand search, written and oral enquiries, as well as interviews with experts. A total of 200 texts were used to prepare this report.

Results: At 92.5% (as of 2004) based on the whole of Germany, the current immunisation coverage for measles in children is above the weighted EC-15-average of 90.67%. Statements can only be made regarding the probability of illness for measles, as no data is available for mumps and rubella. With 2.8 infections (per 100,000 residents) in 2006, Germany has not achieved the WHO target. Of cases submitted to the laboratory, only 32% were validated by diagnostic laboratory findings and 45% confirmed clinical-epidemiologically. There are only few economic analyses of vaccination programs in Germany. In international publications, mainly measels are validated economically. An analysis of the cost of measles for Germany shows potential cost savings. Unfortunately, no complete economic evaluation (cost-effectiveness, cost-benefit, or cost-utility analyses) for MMR vaccination has been performed for Germany. Analyses conducted in the US and a model calculation for a hypothetical Western-European country show a considerable cost saving potential for society in general as well as for the health care system. INTERVENTIONS TO INCREASE THE IMMUNISATION RATE WERE CATEGORIZED IN THREE MAIN GROUPS ACCORDING TO THEIR GOALS: interventions increasing the demand for vaccinations, those improving access to vaccination services and those aiming at the providers (e.g. physicians) of vaccinations.

Discussion: Various studies concluded that reminders to clients, provided in written, electronic or oral form, are a highly recommendable intervention. Provider based interventions were also strongly advised. DESPITE EFFORTS MADE DURING THE PAST YEARS TO ACHIEVE HERD IMMUNITY IN GERMANY, SOME DEFICITS REMAIN: i. e. there are still ample regional differences between and within German federal states.

Conclusions: In the authors' opinion, a key point in increasing immunisation coverage is the development of a binding vaccination program for Germany with regionally differentiated immunisation targets. During the development of such a program, special emphasis should be placed on determining responsibilities of the federal government, the Laender and health insurance funds (e. g. in the case of a measles outbreak).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信